Advertisements

Назо Спрей

Quick links to important sections

Назо Спрей

Selected form

Advertisements
Advertisements

Treatment option: Fever, Rhinorrhea, Rhinitis, Hay Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Назо Спрей

Quick Facts

Property Description
Active ingredient Oxymetazoline hydrochloride
Form Intranasal solution (Nasal spray)
Pharmacological class Alpha-Adrenergic Agonist / Sympathomimetic Agent
General purpose Relief of nasal congestion
Origin Synthetic Imidazoline derivative

Pharmacological Identity and Origin

Назо Спрей is a pharmaceutical preparation defined by its active component, Oxymetazoline hydrochloride, a synthetic Imidazoline derivative belonging to the high-level pharmacological class of alpha-adrenergic agonists. The medication is classified as a direct-acting sympathomimetic agent intended for topical intranasal administration. Oxymetazoline functions primarily as a local vasoconstrictor, an effect that reduces swelling in mucosal tissues. This action is the fundamental basis for its intended general use in easing discomfort during conditions like the common cold.

Composition, Form, and General Purpose

The distinguishing characteristic of Назо Спрей is its formulation as an intranasal solution administered via a nasal spray device, a delivery system designed for precise, localized application to the nasal lining. The core active component, Oxymetazoline hydrochloride, is dissolved in an aqueous solution base, which includes stabilizing excipients. Crucially, Назо Спрей is a multicomponent product often incorporating aromatic substances such as camphor, menthol, and eucalyptol, which provide sensory attributes and distinguish the product experience from plain aqueous Oxymetazoline solutions. The primary pharmacological purpose of Oxymetazoline is to cause local vasoconstriction in the nasal mucosa. This localized effect enables the medicine to achieve its general purpose: providing prompt, localized relief from the feelings of stuffy nose and sinus congestion by effectively reducing tissue swelling.

Advertisements

What side effects are possible with Назо Спрей?

Possible Side Effects and Safety Information

The safety profile for Oxymetazoline hydrochloride in Назо Спрей is established by official government regulatory documentation. The side effects are commonly classified based on how frequently they appear and the body system affected.


Common and Local Adverse Reactions

The most frequently reported reactions are localized to the application site, affecting the Respiratory System. These are typically described as temporary discomfort and include burning, stinging, or dryness inside the nose, as well as sneezing and an increase in nasal discharge.

Systemic and Less Common Effects

As a sympathomimetic agent, less common adverse reactions are documented due to potential low-level systemic absorption. These effects include disturbances in the Nervous System such as headache, dizziness, nervousness, or insomnia. Effects on the Cardiovascular System have also been noted in regulatory data, specifically tachycardia (fast heart rate), palpitations, and increases in blood pressure (hypertension). In some international regulatory texts, these systemic effects are classified as very rare.


Duration-Related Safety Patterns

A distinct and important safety pattern is the potential for rebound nasal congestion, officially termed rhinitis medicamentosa or a worsening of nasal stuffiness. Regulatory texts explicitly link this reaction to prolonged or frequent use of the medication, particularly when used for periods exceeding the recommended duration.

Population-Specific Safety Considerations

Official labeling includes safety constraints for certain groups. Caution is advised for individuals with pre-existing health conditions such as heart disease, high blood pressure, diabetes, or thyroid disease. Furthermore, accidental ingestion by young children is associated with the risk of severe adverse events, including profound sedation and decreased heart rate.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

This information is derived from government regulatory documents and describes the officially documented risks and mandatory actions following an overdose of Назо Спрей (Oxymetazoline hydrochloride).

Property Official Regulatory Statement
Documented overdose presentations Symptoms can reflect both sympathetic activation (e.g., tachycardia, hypertension, spasms, fever) and subsequent CNS/cardiorespiratory depression (e.g., somnolence, bradycardia, shock-like hypotension, loss of consciousness).
Physiological systems affected (as stated in label) Central Nervous System, Cardiovascular System, and Respiratory System.
Population-specific overdose notes (if applicable) Children are explicitly noted as being especially sensitive to systemic effects of these medicines, with accidental ingestion in young children posing a serious risk.
Emergency-response statements The stomach should be emptied by emesis or gastric lavage following ingestion, followed by repeated doses of activated charcoal. Treatment is primarily symptomatic and supportive, and vasopressor drugs are contraindicated.

When Immediate Medical Help is Required

Urgent medical help is required immediately in the event of suspected overdose or accidental oral ingestion (swallowing the medication).

  • Seek immediate medical attention for suspected overdose or accidental swallowing.
  • Contact a local poison control center or emergency services right away if the medication is ingested, especially by a child.

Officially documented severe outcomes include serious systemic events such as cardiac arrest, apnoea, and oedema of the lungs. Continuous monitoring of vital signs, including blood pressure, pulse, and level of consciousness, is a required part of managing the overdose state.

Advertisements

Therapeutic Uses of Назо Спрей

What Назо Спрей Treats: Main Uses and Benefits

Назо Спрей is commonly used across domains where additional symptomatic support is needed, primarily addressing several distinct clinical contexts marked by nasal obstruction.

The medication helps address symptom clusters that may become intense or disruptive, and is relevant for managing symptoms that interfere with daily comfort across conditions characterized by periods of heightened symptoms. Its indications include providing supportive relief from nasal congestion associated with the common cold, seasonal allergic rhinitis (hay fever), and sinus pressure.

It is generally applied in scenarios where short-term symptomatic assistance is needed during phases when symptoms become more noticeable, relevant in contexts involving heightened systemic burden, such as those that interfere with rest or occur during allergy seasons. The supportive relief offered helps patients cope more steadily with symptom fluctuations.

“The therapeutic benefit supports easing the physical discomfort of a blocked nose and contributes to improved functional stability during symptomatic episodes.”


Quick Fact: Relief for Nasal Airflow Obstruction

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and provides support that helps ease the overall symptom burden associated with nasal swelling and blockage. This assistance is particularly valuable when congestion leads to feelings of sinus fullness and interferes with routine activities.

Regulatory References

  1. FDA DailyMed official label
Advertisements

Eligibility and Restrictions for Use

This section summarizes official regulatory information defining the population eligible for Назо Спрей, as established in government-authorized labeling.

Populations Excluded (Contraindications)

The medicine is strictly contraindicated (must not be used) in several specific patient populations based on officially documented regulatory rules. These include:

  • Individuals with a known hypersensitivity or allergy to the active substance (Oxymetazoline) or any other component (excipient) present in the spray formulation.
  • Patients diagnosed with atrophic rhinitis (a chronic, progressive disease of the nasal mucous membrane).
  • Those with unhealed wounds or ulcers of the nasal septum, or who have recently undergone nasal surgery or experienced trauma to the nose.
  • Patients with elevated intraocular pressure, particularly closed-angle glaucoma.
  • Individuals currently taking Monoamine Oxidase Inhibitors (MAOIs) or who have stopped taking them within the past two weeks, due to the potential for interaction.
  • Those with severe forms of cardiovascular disease, such as ischemic heart disease or uncontrolled arterial hypertension.

Restrictions and Special Considerations

Use is also subject to special caution or is not recommended in other groups, including patients with metabolic disorders such as hyperthyroidism (overactive thyroid), diabetes mellitus, or pheochromocytoma (a rare tumor of the adrenal glands).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Назо Спрей (Oxymetazoline hydrochloride) is characterized by officially documented pharmacodynamic interactions that can potentiate cardiovascular effects, based on its status as an alpha-adrenergic agonist.

Formally Documented Interaction Risks

Category Interacting Agents Regulatory Requirement/Restriction
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Use is strictly prohibited. A 14-day washout period after MAOI discontinuation is mandated.
Use with Caution Tricyclic/Tetracyclic Antidepressants Risk of potentiated pressor effects (hypertension, arrhythmia).
Use with Caution Other Sympathomimetic Agents Risk of additive sympathetic stimulation and cardiovascular toxicity.
Use with Caution Ergot Alkaloids Potential for additive vasoconstrictor effects.

Regulatory documentation emphasizes that co-administration with MAOIs carries a significant risk of hypertensive crisis and must be strictly avoided. This prohibition applies to all MAOI examples, including Phenelzine and Tranylcypromine, and necessitates a mandated time separation of fourteen days. The concomitant use of other agents that affect blood pressure, such as Tricyclic Antidepressants or other decongestants, is restricted due to the official finding of pharmacodynamic potentiation.

No clinically significant pharmacokinetic interactions (CYP-related or transporter-mediated) are formally documented in official prescribing information as requiring dose adjustments for this product. Official labels do not explicitly document interactions with food, alcohol, or herbal products.

Advertisements

Mechanism of Action

alpha-Adrenergic Agonism and Local Vasoconstriction

The active component functions as a direct-acting sympathomimetic agent by binding to and activating Alpha-1 (alpha1) and Alpha-2 (alpha2) Adrenergic Receptors located on the blood vessel walls of the nasal mucosa. This receptor activation initiates a rapid molecular cascade that immediately increases the contractile tone of the vascular smooth muscle, thereby causing local vasoconstriction.

Physiological Consequence: Tissue Volume Reduction

The pharmacological action of local vasoconstriction physically reduces the blood flow and volume within the nasal lining. This primary physiological effect physically reduces the volume of mucosal tissue (edema). The direct consequence of the drug's mechanism on tissue volume involves structural expansion of the nasal airway lumen.

Mechanistic Limitation: Receptor Desensitization

Extended or excessive use can lead to receptor desensitization (tachyphylaxis), a state where the alpha-adrenergic receptors become less responsive to the drug's signaling. This functional limitation on the core mechanism is linked to a potential paradoxical rebound in mucosal tissue volume.

Advertisements

Dosage and Administration Information

The usage parameters for Oxymetazoline nasal spray establish the principles for its administration. This medication is exclusively administered via the topical intranasal route as a 0.05% solution.

Dosing and Frequency Limits

The standard regimen for adults and children 6 years of age and older involves administering 2 or 3 sprays into each nostril per dose. This specific dosage of the 0.05% concentration must not be repeated more often than every 10 to 12 hours. The regimen is strictly limited to a maximum of 2 doses in any 24-hour period, a critical factor in the prescribed use pattern.

Administration Principles and Duration

The product is designated for short-term use only, and administration should not exceed 3 consecutive days. Successful application requires adherence to specific procedural conditions, including maintaining an upright head position during application. The spray is delivered by squeezing the bottle quickly and firmly. For hygiene, the container is intended for single-person use only.

Age-Group Use

While the standard dosage pattern is applicable to children 6 to under 12 years of age, administration must occur under adult supervision to ensure proper technique. Use in children under 6 years of age is not supported without seeking specific guidance from a healthcare professional.

Advertisements

Recent Clinical Evidence

Назо Спрей: Recent Clinical Evidence

Evidence for Symptomatic Relief of Nasal Congestion

Studies have examined the product’s application in individuals experiencing nasal congestion, a symptom arising from conditions characterized by fluctuating or episodic manifestations, such as the common cold or allergic rhinitis. Research examined the product’s use in adults experiencing acute episodes. The main goal of this research was to examine outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort associated with nasal obstruction. The findings from these clinical trials contribute to understanding how patients reported their experience. The studies describe patterns observed in the measurements taken, particularly regarding congestion severity scores.

Study Design and Patient Populations

The core evidence supporting the product’s regulatory status comes from Randomized Controlled Trials (RCTs) controlled against an inactive "vehicle" spray. This design is used in research exploring how symptoms change over time. Researchers monitored patient-reported discomfort scores and objective measurements of nasal airflow. Studies primarily focused on healthy adults, although research also examined use in pediatric populations, specifically for children aged 6 years and older. Evidence is limited concerning use in older adults and individuals with certain chronic health conditions, meaning results apply primarily to the populations studied.

Long-Term Research and Scientific Gaps

The trials supporting the product’s use have generally focused on short-term symptom changes, resulting in limited follow-up durations (typically three to ten days of application). Therefore, there is limited information for long-term outcomes of continuous use, and long-term effects are not fully characterized. Scientific literature highlights an area of uncertainty regarding prolonged application: the risk of rebound nasal congestion may be associated with use that significantly exceeds the recommended short-term duration. Research is ongoing to better understand its associated patterns and frequency, as comparative evidence is lacking and data for continuous use are limited.

Key Studies & References

  1. Label: AFRIN- oxymetazoline hydrochloride spray (FDA DailyMed)
  2. Is Afrin (Oxymetazoline) A Safe And Effective Drug In Normal, Healthy Adults With Reference To Nasal Congestion And (Systematic Review)
  3. Rhinitis Medicamentosa - StatPearls (Source on Rebound Congestion)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Назо Спрей (FAQ)


Q: How quickly should I feel the effect of Назо Спрей?

Official drug information indicates that the effect of the nasal spray is designed to start quickly. The medication acts on blood vessels shortly after administration, and product information suggests that relief may begin within a few minutes.

Q: What's the difference between Назо Спрей and a nasal decongestant?

Назо Спрей is classified as a type of nasal decongestant. Its active ingredient, oxymetazoline, is a direct-acting sympathomimetic agent, meaning it works locally to constrict blood vessels and reduce swelling in the nasal lining.

Q: Can I use this spray if I am taking blood pressure medicine?

Regulatory guidelines recommend that individuals with high blood pressure or heart disease discuss the use of this product with a healthcare professional beforehand. As a sympathomimetic agent, it may interact with other medicines, including some used to manage blood pressure, due to the potential for compounded cardiovascular effects.

Q: Does using Назо Спрей affect my ability to drive?

Less common systemic effects, such as dizziness, nervousness, or headaches, are noted in regulatory information. Regulatory information notes that if these effects occur, activities requiring attention, such as driving or operating machinery, should be approached with caution.

Q: What is the significance of the research evidence for Назо Спрей?

The research evidence supporting the product is significant because it describes the drug's short-term effectiveness for the temporary relief of nasal congestion. Importantly, the studies also established the critical short-term use limits that must be followed to help minimize the risk of rebound congestion.

Q: Does the spray cause drowsiness?

Official side effect listings include insomnia (difficulty sleeping) and nervousness as less common systemic effects, which are generally stimulating. Drowsiness is not typically listed as a reported side effect of this medication.

Q: Does using the spray affect my body's natural mucus production?

The primary action of the spray is to reduce swelling in the nasal lining. However, an increase in nasal discharge or moisture is listed in regulatory texts as a potential local side effect, separate from the main congestion relief mechanism.

Q: Are there different strengths or versions of Назо Спрей?

The standard solution for adults and children aged 6 and older is the 0.05% strength. Some regulatory documents reference a 0.025% strength, but this is for use only as directed by a healthcare professional.

Q: What happens if I miss a scheduled use of the spray?

This medication is generally used on an as-needed basis for congestion relief. If a dose is missed when following a doctor-advised schedule and it is almost time for the next dose, it is recommended to skip the missed application. Compensating for a missed dose by using a double dose is not advised.

Q: Is Назо Спрей safe for use during pregnancy?

Official regulatory documents do not provide a definitive safety conclusion for use during pregnancy. It is recommended that individuals who are pregnant or planning to become pregnant consult a healthcare professional before use.

Q: Can someone use this spray while breastfeeding?

Official information indicates that individuals who are breastfeeding should consult a healthcare professional before use. A healthcare provider can determine if the benefit of using the product outweighs any potential concerns.

Q: Does Назо Спрей interact with any common over-the-counter pain relievers?

The official interaction table focuses on agents that affect blood pressure, such as MAOIs and certain antidepressants. While common OTC pain relievers like ibuprofen or acetaminophen are not typically listed with a primary interaction, official guidance includes informing a healthcare professional about all medications being taken.

Q: Is it necessary to shake the bottle before using Назо Спрей?

Administration instructions indicate that the bottle should be shaken well before use to ensure the solution is properly mixed.

Q: How do I clean the nozzle of the spray container?

Hygiene instructions generally indicate that the nozzle should be wiped clean after use and the cap secured. This helps ensure the container remains sanitary for single-person use.

Q: How long after opening the bottle should I discard the spray?

While a specific period is not always on the retail label, certain international regulatory documents, such as the European Summary of Product Characteristics, recommend discarding the container 28 days after it is first opened, regardless of how much medicine remains.

Q: Is the spray preservative-free?

Most common formulations of this medicine are not preservative-free. The official label usually lists inactive ingredients, which often include preservatives such as Benzalkonium Chloride (BAK).

Q: If I have kidney problems, is the use of Назо Спрей a concern?

General safety information advises caution for users with pre-existing chronic health conditions. Although official labeling does not include specific dosage adjustments for altered kidney function, if there are concerns about kidney function, regulatory safety principles indicate that the use should be reviewed with a healthcare provider.

Q: Can using the spray result in nosebleeds?

Nosebleeds (epistaxis) are not commonly listed as a primary side effect, but the localized adverse reactions include dryness and irritation of the nasal lining. This dryness may increase the likelihood of experiencing a nosebleed.

Q: What if I accidentally spray the medicine into my eye?

If the medicine is accidentally sprayed into the eye, the official guidance is to rinse the affected eye immediately with plenty of water or a saline solution. If irritation or effects persist, individuals should seek medical attention.

Q: Is there a generic version of Назо Спрей available?

Yes, the active ingredient in the spray, Oxymetazoline hydrochloride, is a generic medication. As such, it is widely available under various generic labels and other brand names in addition to Назо Спрей.

Advertisements

How should Назо Спрей be stored and disposed of?

The storage and disposal of Назо Спрей (Oxymetazoline hydrochloride) must strictly adhere to regulatory guidelines to ensure stability and safety.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess heat, light, and moisture. Do not freeze or refrigerate the product.
Container Store in the original container, with the cap tightly closed .
Child Safety Keep out of the sight and reach of children .

Official Disposal Instructions

Expired or unused nasal spray must be disposed of properly. The regulatory standard is to not flush the medication down the toilet or pour it into a drain. The preferred method for disposal is to utilize a community drug take-back program or official mail-back envelope. If a take-back program is unavailable, mix the medicine with an undesirable substance (like coffee grounds or kitty litter) in a sealed bag and discard it in the household trash, following local waste regulations . The container must be discarded after the expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Назо Спрей found in:

A-Z Index: